Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
CEL-SCI Co. stock logo
CVM
CEL-SCI
$1.44
-0.7%
$1.89
$1.04
$3.23
$77.73M1.29289,390 shs136,600 shs
Forian Inc. stock logo
FORA
Forian
$2.72
$2.97
$1.85
$4.15
$84.68M1.0326,220 shs15,000 shs
MSP Recovery, Inc. stock logo
LIFW
MSP Recovery
$1.01
+8.0%
$1.02
$0.65
$17.48
$141.37M-2.011.98 million shs310,700 shs
Cartesian Therapeutics, Inc. stock logo
RNAC
Cartesian Therapeutics
$21.03
+0.6%
$19.20
$11.66
$42.60
$113.35M0.5746,227 shs123,800 shs
10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
CEL-SCI Co. stock logo
CVM
CEL-SCI
0.00%-7.69%-24.61%-49.65%-36.56%
Forian Inc. stock logo
FORA
Forian
0.00%+2.65%-18.07%+3.42%+2.26%
MSP Recovery, Inc. stock logo
LIFW
MSP Recovery
0.00%+6.54%+47.45%-17.89%-93.49%
Cartesian Therapeutics, Inc. stock logo
RNAC
Cartesian Therapeutics
0.00%+17.42%+7.85%-11.53%+2,102,999,900.00%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
CEL-SCI Co. stock logo
CVM
CEL-SCI
N/AN/AN/AN/AN/AN/AN/AN/A
Forian Inc. stock logo
FORA
Forian
2.0319 of 5 stars
3.52.00.00.01.11.71.3
MSP Recovery, Inc. stock logo
LIFW
MSP Recovery
0.5799 of 5 stars
0.03.00.00.01.92.50.6
Cartesian Therapeutics, Inc. stock logo
RNAC
Cartesian Therapeutics
2.3843 of 5 stars
3.50.00.00.03.25.00.0

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
CEL-SCI Co. stock logo
CVM
CEL-SCI
N/AN/AN/AN/A
Forian Inc. stock logo
FORA
Forian
3.00
Buy$7.67181.86% Upside
MSP Recovery, Inc. stock logo
LIFW
MSP Recovery
N/AN/AN/AN/A
Cartesian Therapeutics, Inc. stock logo
RNAC
Cartesian Therapeutics
3.00
Buy$45.00113.98% Upside

Current Analyst Ratings

Latest FORA, RNAC, LIFW, and CVM Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/23/2024
Cartesian Therapeutics, Inc. stock logo
RNAC
Cartesian Therapeutics
Leerink Partnrs
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform
4/23/2024
Cartesian Therapeutics, Inc. stock logo
RNAC
Cartesian Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$2.00 ➝ $54.00
4/23/2024
Cartesian Therapeutics, Inc. stock logo
RNAC
Cartesian Therapeutics
SVB Leerink
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$39.00
4/9/2024
Cartesian Therapeutics, Inc. stock logo
RNAC
Cartesian Therapeutics
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy ➝ Buy$42.00
4/4/2024
Forian Inc. stock logo
FORA
Forian
Roth Mkm
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$5.00
3/18/2024
Cartesian Therapeutics, Inc. stock logo
RNAC
Cartesian Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$60.00
3/4/2024
Cartesian Therapeutics, Inc. stock logo
RNAC
Cartesian Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$60.00
(Data available from 4/29/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
CEL-SCI Co. stock logo
CVM
CEL-SCI
N/AN/AN/AN/A$0.28 per shareN/A
Forian Inc. stock logo
FORA
Forian
$20.48M4.13N/AN/AN/A
MSP Recovery, Inc. stock logo
LIFW
MSP Recovery
$7.70M18.36$2.89 per share0.35$10.22 per share0.10
Cartesian Therapeutics, Inc. stock logo
RNAC
Cartesian Therapeutics
$26M4.36N/AN/A($85.17) per share-0.25

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
CEL-SCI Co. stock logo
CVM
CEL-SCI
-$32.19M-$0.68N/AN/AN/AN/A-204.28%-95.72%5/10/2024 (Estimated)
Forian Inc. stock logo
FORA
Forian
N/A$0.338.24N/AN/AN/AN/A5/10/2024 (Estimated)
MSP Recovery, Inc. stock logo
LIFW
MSP Recovery
-$56.35MN/A0.00N/A-731.32%-12.92%-6.63%7/15/2024 (Estimated)
Cartesian Therapeutics, Inc. stock logo
RNAC
Cartesian Therapeutics
-$219.71MN/A0.00N/AN/A-845.01%-58.21%-27.22%5/2/2024 (Estimated)

Latest FORA, RNAC, LIFW, and CVM Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
3/28/2024Q4 2023
Forian Inc. stock logo
FORA
Forian
N/A-$0.01-$0.01-$0.06$5.72 million$5.37 million
3/7/2024Q4 2023
Cartesian Therapeutics, Inc. stock logo
RNAC
Cartesian Therapeutics
-$0.30-$2.40-$2.10$1.23N/A$8.27 million
2/14/2024Q1 2024
CEL-SCI Co. stock logo
CVM
CEL-SCI
N/A-$0.14-$0.14-$0.14N/AN/A

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
CEL-SCI Co. stock logo
CVM
CEL-SCI
N/AN/AN/AN/AN/A
Forian Inc. stock logo
FORA
Forian
N/AN/AN/AN/AN/A
MSP Recovery, Inc. stock logo
LIFW
MSP Recovery
N/AN/AN/AN/AN/A
Cartesian Therapeutics, Inc. stock logo
RNAC
Cartesian Therapeutics
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
CEL-SCI Co. stock logo
CVM
CEL-SCI
0.75
1.26
0.78
Forian Inc. stock logo
FORA
Forian
N/AN/AN/A
MSP Recovery, Inc. stock logo
LIFW
MSP Recovery
0.48
0.47
0.47
Cartesian Therapeutics, Inc. stock logo
RNAC
Cartesian Therapeutics
N/A
1.33
1.33

Ownership

Institutional Ownership

CompanyInstitutional Ownership
CEL-SCI Co. stock logo
CVM
CEL-SCI
12.08%
Forian Inc. stock logo
FORA
Forian
19.25%
MSP Recovery, Inc. stock logo
LIFW
MSP Recovery
3.77%
Cartesian Therapeutics, Inc. stock logo
RNAC
Cartesian Therapeutics
86.95%

Insider Ownership

CompanyInsider Ownership
CEL-SCI Co. stock logo
CVM
CEL-SCI
16.24%
Forian Inc. stock logo
FORA
Forian
31.30%
MSP Recovery, Inc. stock logo
LIFW
MSP Recovery
19.40%
Cartesian Therapeutics, Inc. stock logo
RNAC
Cartesian Therapeutics
31.20%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
CEL-SCI Co. stock logo
CVM
CEL-SCI
N/A53.98 million45.21 millionOptionable
Forian Inc. stock logo
FORA
Forian
10231.13 millionN/AOptionable
MSP Recovery, Inc. stock logo
LIFW
MSP Recovery
100139.97 million112.81 millionOptionable
Cartesian Therapeutics, Inc. stock logo
RNAC
Cartesian Therapeutics
375.39 million3.71 millionOptionable

FORA, RNAC, LIFW, and CVM Headlines

SourceHeadline
Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Short Interest UpdateCartesian Therapeutics, Inc. (NASDAQ:RNAC) Short Interest Update
marketbeat.com - April 28 at 9:19 PM
Leerink Partnrs Weighs in on Cartesian Therapeutics, Inc.s Q1 2024 Earnings (NASDAQ:RNAC)Leerink Partnrs Weighs in on Cartesian Therapeutics, Inc.'s Q1 2024 Earnings (NASDAQ:RNAC)
americanbankingnews.com - April 26 at 1:26 AM
Q1 2024 Earnings Estimate for Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Issued By HC WainwrightQ1 2024 Earnings Estimate for Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Issued By HC Wainwright
americanbankingnews.com - April 26 at 1:26 AM
Wall Street Analysts Believe Cartesian Therapeutics, Inc. (RNAC) Could Rally 146.24%: Heres is How to TradeWall Street Analysts Believe Cartesian Therapeutics, Inc. (RNAC) Could Rally 146.24%: Here's is How to Trade
zacks.com - April 25 at 10:56 AM
Cartesian Therapeutics, Inc. (NASDAQ:RNAC) to Post Q1 2024 Earnings of ($0.27) Per Share, HC Wainwright ForecastsCartesian Therapeutics, Inc. (NASDAQ:RNAC) to Post Q1 2024 Earnings of ($0.27) Per Share, HC Wainwright Forecasts
marketbeat.com - April 25 at 7:23 AM
Leerink Partnrs Weighs in on Cartesian Therapeutics, Inc.s FY2027 Earnings (NASDAQ:RNAC)Leerink Partnrs Weighs in on Cartesian Therapeutics, Inc.'s FY2027 Earnings (NASDAQ:RNAC)
americanbankingnews.com - April 25 at 4:18 AM
Leerink Partnrs Reiterates "Outperform" Rating for Cartesian Therapeutics (NASDAQ:RNAC)Leerink Partnrs Reiterates "Outperform" Rating for Cartesian Therapeutics (NASDAQ:RNAC)
americanbankingnews.com - April 25 at 3:37 AM
Equities Analysts Issue Forecasts for Cartesian Therapeutics, Inc.s Q1 2025 Earnings (NASDAQ:RNAC)Equities Analysts Issue Forecasts for Cartesian Therapeutics, Inc.'s Q1 2025 Earnings (NASDAQ:RNAC)
americanbankingnews.com - April 25 at 2:58 AM
FY2027 Earnings Forecast for Cartesian Therapeutics, Inc. Issued By Leerink Partnrs (NASDAQ:RNAC)FY2027 Earnings Forecast for Cartesian Therapeutics, Inc. Issued By Leerink Partnrs (NASDAQ:RNAC)
marketbeat.com - April 24 at 6:50 AM
Leerink Partnrs Reiterates Outperform Rating for Cartesian Therapeutics (NASDAQ:RNAC)Leerink Partnrs Reiterates Outperform Rating for Cartesian Therapeutics (NASDAQ:RNAC)
marketbeat.com - April 24 at 5:55 AM
Cartesian Therapeutics (NASDAQ:RNAC) Now Covered by Analysts at SVB LeerinkCartesian Therapeutics (NASDAQ:RNAC) Now Covered by Analysts at SVB Leerink
americanbankingnews.com - April 24 at 4:44 AM
Cartesian Therapeutics (NASDAQ:RNAC) Price Target Increased to $54.00 by Analysts at HC WainwrightCartesian Therapeutics (NASDAQ:RNAC) Price Target Increased to $54.00 by Analysts at HC Wainwright
americanbankingnews.com - April 24 at 4:44 AM
Buy Rating Affirmed for Cartesian Therapeutics: Promising CAR-T Therapy and Strategic Financial MovesBuy Rating Affirmed for Cartesian Therapeutics: Promising CAR-T Therapy and Strategic Financial Moves
markets.businessinsider.com - April 23 at 2:52 PM
Cartesian Therapeutics (NASDAQ:RNAC) Price Target Raised to $54.00 at HC WainwrightCartesian Therapeutics (NASDAQ:RNAC) Price Target Raised to $54.00 at HC Wainwright
marketbeat.com - April 23 at 7:15 AM
Cartesian Therapeutics to Present at the ASGCT 27th Annual MeetingCartesian Therapeutics to Present at the ASGCT 27th Annual Meeting
businesswire.com - April 22 at 4:30 PM
Marinus Pharmaceuticals, Cartesian Therapeutics, Adial Pharmaceuticals among healthcare moversMarinus Pharmaceuticals, Cartesian Therapeutics, Adial Pharmaceuticals among healthcare movers
msn.com - April 15 at 10:51 AM
Down -30.75% in 4 Weeks, Heres Why You Should You Buy the Dip in Cartesian Therapeutics, Inc. (RNAC)Down -30.75% in 4 Weeks, Here's Why You Should You Buy the Dip in Cartesian Therapeutics, Inc. (RNAC)
zacks.com - April 8 at 10:35 AM
Cartesian Therapeutics (NASDAQ:RNAC) Sets New 1-Year Low at $13.19Cartesian Therapeutics (NASDAQ:RNAC) Sets New 1-Year Low at $13.19
marketbeat.com - April 5 at 12:21 PM
Cartesian Therapeutics to Participate in the 23rd Annual Needham Virtual Healthcare ConferenceCartesian Therapeutics to Participate in the 23rd Annual Needham Virtual Healthcare Conference
businesswire.com - April 4 at 7:30 AM
Cartesian Therapeutics Announces New Employment Inducement GrantsCartesian Therapeutics Announces New Employment Inducement Grants
businesswire.com - April 4 at 7:00 AM
Short Interest in Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Expands By 27.3%Short Interest in Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Expands By 27.3%
marketbeat.com - April 1 at 8:31 AM
Cartesian Therapeutics Announces Approval of Conversion of Series A Convertible Preferred Stock and Plans to Effect Reverse Stock SplitCartesian Therapeutics Announces Approval of Conversion of Series A Convertible Preferred Stock and Plans to Effect Reverse Stock Split
globenewswire.com - March 28 at 4:05 PM
Insider Buying: Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Director Buys 19,044 Shares of StockInsider Buying: Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Director Buys 19,044 Shares of Stock
insidertrades.com - March 21 at 10:47 AM
Cartesian Therapeutics Director Acquires 3.2% More StockCartesian Therapeutics Director Acquires 3.2% More Stock
finance.yahoo.com - March 21 at 9:00 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

CEL-SCI logo

CEL-SCI

NYSE:CVM
CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development of immune system therapy for the treatment of cancer and other diseases in the United States. The company's lead immunotherapy is Multikine, which has completed Phase 3 clinical trials for the potential treatment of certain head and neck cancers. It is also developing products based on its proprietary technology Ligand Epitope Antigen Presentation System (LEAPS) technology, a patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, parasitic infections, autoimmune conditions, allergies, transplantation rejections, and cancer. In addition, the company's product pipeline includes CEL-2000; CEL-4000; and CEL-5000, which are LEAPS-based product candidates in preclinical trials for the treatment of rheumatoid arthritis disease. CEL-SCI Corporation was incorporated in 1983 and is headquartered in Vienna, Virginia.
Forian logo

Forian

NASDAQ:FORA
Forian Inc. provides software and information solutions, proprietary data driven insights, and predictive analytics to optimize and measure the operational, clinical, and financial performance of its life science and healthcare customers. It operates through three segments: Information & Software, Services, and Other. The company's products include BioTrack, a vertically integrated point of sale, manufacturing, delivery, and cultivator software solution for dispensaries, cultivators, manufacturers, and distributors; and Cannalytics, a Software as a Service based analytics solution that provides customers with a presentation of business performance. Its products also comprise BioTrack seed-to-sale compliance traceability platform, which is used to manage the tracking and tracing of various cannabis products from cultivation to sale; and BioTrack State Traceability & Enforcement Monitoring System to ensure transparency and accountability throughout cannabis supply chain. In addition, the company offers security monitoring and web marketing services. Forian Inc. was incorporated in 2020 and is headquartered in Newtown, Pennsylvania. Forian Inc.
MSP Recovery logo

MSP Recovery

NASDAQ:LIFW
MSP Recovery, Inc., doing business as LifeWallet, operates as a healthcare recoveries and data analytics company in the United States and Puerto Rico. The company offers claims recovery services, including services to related parties or third parties to assist entities with pursuit of claims recovery rights. It is also developing LifeWallet, a platform for real-time analytics at the point of care which helps in identifying the primary insurer and assisting providers in receiving customary rates for accident-related treatment. MSP Recovery, Inc. was founded in 2014 and is headquartered in Coral Gables, Florida.
Cartesian Therapeutics logo

Cartesian Therapeutics

NASDAQ:RNAC
Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, engages in the provision of mRNA cell therapies for the treatment of autoimmune diseases. It develops Descartes-08, an autologous anti-BCMA RNA-engineered chimeric antigen receptor T-cell therapy, currently under Phase 2b clinical development for generalized myasthenia gravis, as well as for patients with systemic lupus erythematosus, and myeloma autoimmune basket trials for other autoimmune diseases. The company develops Descartes-15 to treat Autoimmune diseases, myeloma; and Descartes-33 which is in preclinical development for treatment of autoimmune diseases. Cartesian Therapeutics, Inc. is headquartered in Gaithersburg, Maryland.